Last reviewed · How we verify

TC

AGO Study Group · FDA-approved active Small molecule

TC is a chemotherapy regimen combining docetaxel and cyclophosphamide, which work synergistically to inhibit cell division and induce apoptosis in cancer cells.

TC is a chemotherapy regimen combining docetaxel and cyclophosphamide, which work synergistically to inhibit cell division and induce apoptosis in cancer cells. Used for Breast cancer (adjuvant and neoadjuvant treatment).

At a glance

Generic nameTC
Also known asPaclitaxel/Carboplatin, Docetaxel plus cyclophosphamide
SponsorAGO Study Group
Drug classChemotherapy combination regimen
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Docetaxel is a taxane that stabilizes microtubules and prevents their disassembly, disrupting mitotic spindle formation. Cyclophosphamide is an alkylating agent that cross-links DNA, preventing replication. Together, they provide complementary cytotoxic mechanisms commonly used in breast cancer treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results